Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study
Abiraterone, enzalutamide, and apalutamide have comparable oncologic outcomes in terms of OS, CSS, and time to CRPC in patients with high-risk mHSPC. Our data on differential treatment discontinuation rates, PSA response, and AE profiles can help guide clinical decision-making.
Authors
- Shingo Hatakeyama (ORCID: https://orcid.org/0000-0002-0026-4079)
- Tomonori Habuchi (ORCID: https://orcid.org/0000-0003-0998-4432)
- Fumihiko Urabe (ORCID: https://orcid.org/0000-0002-2599-8183)
- Kosuke Iwatani (ORCID: https://orcid.org/0000-0001-5428-852X)
- Wataru Fukuokaya (ORCID: https://orcid.org/0000-0003-1044-912X)
- Tatsuya Shimomura (ORCID: https://orcid.org/0009-0008-5840-1284)
- Takafumi Yanagisawa (ORCID: https://orcid.org/0000-0002-7410-0712)
- Kojiro Tashiro
- Shintaro Narita (ORCID: https://orcid.org/0000-0003-2988-1860)
- Hidetsugu Takahashi
- Takahiro Kimura
- K Katsumi
- Katsuki Muramoto
- Keiichiro Mori
Institutions
- Jikei University School of Medicine (JP)
- Hirosaki University (JP)
- Akita University (JP)
Publication Details
- Journal
- The Prostate
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1002/pros.24813
- Citations
- 14
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 5.87
Funders
- Mochida Pharmaceutical Company